Share this story:

AREV Notes U.S. Governments $2.9 Billion Assistance to Address Food Insecurity

AREV Life Sciences Global Corp.

VANCOUVER, BC - TheNewswire - September 22, 2022 - AREV Life Sciences Global Corp. (CSE:AREV) (OTC:AREVF) (“AREV” or the “Company”) AREV Life Sciences Global Corporation applauds The U.S. Government for its recent announcement to support global food insecurity.  


On September 21st the U.S. government announced over $2.9 billion in new assistance to address global food insecurity. President Biden’s announcement builds on the $6.9 billion in U.S. government assistance to support global food security already committed this year. As quoted from the announcement, “The compounding impacts of the pandemic, the deepening climate crisis, rising energy and fertilizer costs, and protracted conflicts – including Russia’s invasion of Ukraine – have disrupted global supply chains and dramatically increased global food prices. A multi-year drought in the Horn of Africa has created a dire humanitarian emergency, with parts of Somalia at risk of famine for the second time in just over a decade. This new announcement of $2.9 billion will save lives through emergency interventions and invest in medium to long term food security assistance in order to protect the world’s most vulnerable populations from the escalating global food security crisis.”

“We are encouraged to see this investment in our sector. SUSTAINN™ our Ready to Use Therapeutic Food provides utility in food insecurity and therapeutic affect for vulnerable populations.”, stated Mike Withrow CEO of AREV. He went on to say, “We see this new assistance as confirmation our team has identified a timely market opportunity.”

SUSTAINN™ is being developed in co-operation with the Richard Centre for Food Technologies and Research at the University of Manitoba while we select strategic production locations for the product.


Full White House Release can be read here:


For further information, contact Mike Withrow, 778-929-6536. For more information visit


On behalf of the Board,


Mike Withrow
CEO & Director

About AREV Life Sciences Global Corp.

The Company is a fully integrated enterprise with competencies in: 1) extraction of compounds for consumption and topical use. 2) Clinical Nutrition and 3) A technology platform called Medicine Merchant. The Company produces ingredients and formulates exclusive therapeutic interventions with plans to deliver innovation in clinical nutrition, proprietary supplements, topicals and rational drug design, based on science. The Company’s business model leverages its core competency of extraction to produce ingredients and compounds for its pipeline of products. The Company continues in the product development and pre-commercialization stage.


AREV is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV is a member of both BIOTECanada and The Biotechnology Innovation Organization (BIO).  






Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required

under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements.  Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements

address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on